Please ensure Javascript is enabled for purposes of website accessibility

Why GlaxoSmithKline, Clovis Oncology, and Tesaro Are on the Move Today

By George Budwell - Updated Dec 3, 2018 at 1:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GlaxoSmithKline's first major pharma acquisition in years isn't a hit with shareholders.

What happened

Shares of Tesaro (NASDAQ: TSRO), a mid-cap oncology company, jumped by as much as 59% on heavy volume this morning after the company announced that it had agreed to a $5.1 billion takeover bid from British pharma giant GlaxoSmithKline (GSK 0.52%). Glaxo is reportedly buying Tesaro for its FDA-approved ovarian cancer drug Zejula (niraparib). Zejula belongs to a fairly new class of medicines known as  oral poly ADP-ribose polymerase inhibitors, or PARP inhibitors for short.

Clovis Oncology's (CLVS -3.94%) shares also marched higher by a whopping 31% in early-morning trading today in response to this deal. Clovis sports a PARP inhibitor called Rubraca, which competes head to head with Zejula. Investors appear to be betting that Clovis will be the next PARP developer to catch the eye of a deep-pocketed big pharma or blue-chip biotech.    

"M&A Business" spelled out with wood blocks.

Image Source: Getty Images.

So what

Not surprisingly, Glaxo's shareholders aren't entirely thrilled with this deal, evinced by the drugmaker's shares falling by nearly 8% right out of the gate today. Despite multibillion-dollar peak sales projections for both Tesaro's Zejula and Clovis' Rubraca, these two drugs are nowhere near blockbuster status at this point in their respective commercial launches.

Zejula's third-quarter net sales, for instance, came in at only $63 million for the three-month period. And Rubraca fared even worse, hauling in a mere $22.8 million during the third quarter of 2018. In short, Glaxo may have just grossly overpaid for Tesaro.   

Now what

On the bright side, Zejula still has a shot at living up to these lofty sales projections over the long run. This drug, after all, is presently in a host of clinical trials for other high-value indications, such as breast and prostate cancer. The downside, though, is that Clovis' drug is also pursuing similar indications in its clinical program. So there's a good chance that these two PARP inhibitors will end up competing for market share across many of the same indications. Glaxo, therefore, will need some luck going forward to ensure that this deal turns into a net positive for shareholders and not a costly misstep. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$44.75 (0.52%) $0.23
Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
$0.68 (-3.94%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.